DC Capital
Long/short equity, special situations, event-driven, arbitrage

Dynavax Technologies: 6 Reasons To Buy

While bio-pharmaceutical companies are know for their inherent level of business risk, a fair portion of these companies lie in the upper quartile when it comes to the returns they provide for investors. It's important to recognize that the risk to reward profile is not the same for all companies within the bio-pharmaceutical industry, and there is a considerable number of companies that actually present an asymmetric risk to reward scenario that is quite appealing. With that being said, I would like to highlight a clinical-stage bio-pharmaceutical company focused on treating infectious and inflammatory diseases, Dynavax Technologies (NASDAQ:DVAX). Within the last year, DVAX's shares have quite a bit in the market. From a 52 week high of close...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details